KALAMAZOO – After recently completing the first close on a $2.5 million Series A financing round, Armune BioScience Monday announced the appointment of Susan J. Crookston to the position of Chief Financial Officer to continue the company?s preparation for the launch of Apifiny, its non-PSA blood test to aid in the early detection of prostate cancer.
“As Armune raises additional capital and prepares to launch Apifiny, we are excited to have Sue Crookston join our team as CFO. She brings significant financial experience in early-stage life science companies and we look forward to the complementary strengths she will bring to our team,? said David A. Esposito, President and CEO.
Sue joined the Armune team in September 2014 to prepare for the Series A round and support the transition of Jim Johnson as outgoing CFO. Esposito said, ?We are thankful for the efforts of Jim Johnson in supporting the company since its founding in 2008 and through the transition as we prepare for the launch of Apifiny, our first diagnostic assay.?
Sue has more than 20 years of experience in various financial and human resource roles within the life sciences market, including senior and management team experience at two start-up companies -Afmedica and most recently with CeeTox, Inc. Sue also worked for Apjohn Ventures as the Finance Director, leading a number of key initiatives. Prior to working for start-ups, Sue held various financial leadership and analyst roles in The Upjohn Company, Pharmacia & Upjohn and Pfizer.
Armune BioScience is focused on commercial execution in support of the launch of Apifiny and raising additional funds to complete the $2.5 Million Series A round. The first close of that round was announced earlier.
